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RESEARCH ARTICLE
Pseudomonas aeruginosa Reduces VX-809
Stimulated F508del-CFTR Chloride Secretion
by Airway Epithelial Cells
Bruce A. Stanton*, Bonita Coutermarsh, Roxanna Barnaby, Deborah Hogan
Department of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Hanover, New




P. aeruginosa is an opportunistic pathogen that chronically infects the lungs of 85% of adult
patients with Cystic Fibrosis (CF). Previously, we demonstrated that P. aeruginosa reduced
wt-CFTR Cl secretion by airway epithelial cells. Recently, a new investigational drug VX-
809 has been shown to increase F508del-CFTR Cl secretion in human bronchial epithelial
(HBE) cells, and, in combination with VX-770, to increase FEV1 (forced expiratory volume
in 1 second) by an average of 3-5% in CF patients homozygous for the F508del-CFTR mu-
tation. We propose that P. aeruginosa infection of CF lungs reduces VX-809 + VX-770-
stimulated F508del-CFTR Cl secretion, and thereby reduces the clinical efficacy of VX-809
+ VX-770.
Methods and Results
F508del-CFBE cells and primary cultures of CF-HBE cells (F508del/F508del) were ex-
posed to VX-809 alone or a combination of VX-809 + VX-770 for 48 hours and the effect of
P. aeruginosa on F508del-CFTR Cl secretion was measured in Ussing chambers. The ef-
fect of VX-809 on F508del-CFTR abundance was measured by cell surface biotinylation
and western blot analysis. PAO1, PA14, PAK and 6 clinical isolates of P. aeruginosa (3 mu-
coid and 3 non-mucoid) significantly reduced drug stimulated F508del-CFTR Cl secretion,
and plasma membrane F508del-CFTR.
Conclusion
The observation that P. aeruginosa reduces VX-809 and VX-809 + VX-770 stimulated
F508del CFTR Cl secretion may explain, in part, why VX-809 + VX-770 has modest efficacy
in clinical trials.
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Introduction
CFTR is a cyclic-AMP regulated Cl channel localized to the apical plasma membrane of epithe-
lial cells in the lungs [1–4]. Cl secretion via wt-CFTR is the major driving force for the produc-
tion of a thin layer of liquid overlying the lung epithelium, which is essential for effective
mucociliary transport that mechanically clears debris and pathogens from the airways and,
thereby, serves a vital role in innate immunity [4–6]. Mutations in the CFTR gene cause Cystic
Fibrosis (CF), an autosomal recessive genetic disease that causes progressive loss of lung func-
tion and death in the 3rd decade of life due to a decrease in airway surface liquid and reduced
mucociliary transport, leading to chronic bacterial lung infections [1–3,6]. The F508del muta-
tion in CFTR increases its degradation in the endoplasmic reticulum, dramatically reducing
CFTR mediated Cl secretion [7,8]. In addition, the F508del mutation reduces the half-life of
CFTR and the single channel open probability by ~50% [9,10]. Recently, Vertex Pharmaceuti-
cals developed VX-809 (Lumacaftor), which increases the amount of F508del-CFTR in the
plasma membrane of airway epithelial cells, and VX-770 (Ivacaftor), which increases the open
probability of F508del-CFTR, to be given together to CF patients homozygous for the F508del
CFTR mutation [9,11,12]. Together these drugs increase F508del-CFTR Cl secretion by human
bronchial epithelia cells in Ussing chamber experiments to a level predicted to improve lung
function in CF patients. Clinical trials with a combination of VX-809 + VX-770 have been
promising, with an overall modest improvement in FEV1 of ~3–5% [11].
Previously, we demonstrated that P. aeruginosa reduces wt-CFTR Cl secretion by airway ep-
ithelial cells by a mechanism mediated in part by the secretion of Cif (CFTR inhibitory factor),
a virulence factor present in outer membrane vesicles, which enhances the ubiquitination and
degradation of wt-CFTR [12–14]. Thus, we propose that P. aeruginosa infection of the CF
lungs, which is apparent in ~85% of adult CF patients, reduces VX-809 stimulated F508del-
CFTR Cl secretion, thereby reducing the efficacy of VX-809 + VX-770. Accordingly, the goal of
this study was to test the hypothesis that P. aeruginosa reduces VX-809 stimulated F508del-
CFTR Cl secretion in human CF airway epithelial cells. We report that P. aeruginosa reduced
VX-809, and VX809 + VX-770 stimulated Cl secretion in a CF cell line (CFBE cells) and in CF
primary cultures of human bronchial epithelial (HBE) cells homozygous for F508del-CFTR.
Furthermore, the effects were observed in all nine P. aeruginosa isolates tested, including those
with the alginate-overproducing mucoid phenotype that is common among strains from long-
term CF infections. Because ~85% of adult CF patients are chronically colonized by P. aerugi-
nosa, these observations may explain, in part, why VX-809 + VX-770 has only modest effects
on FEV1 in CF patients with the F508del/F508del-CFTR mutation.
Materials and Methods
Cell culture
Primary CF human bronchial epithelial cells (hereafter referred to as CF-HBE cells) were ob-
tained from the University of North Carolina courtesy of Dr. Scott Randell, and maintained in
culture as described [15]. The Dartmouth Committee for the Protection of Human Subjects
has determined that the use of CF-HBE cells in this study is not considered human subject's
research because cells are taken from discarded tissue and contain no patient identifiers.
CF-HBE cells secrete mucus and have apical cilia. Cells from a minimum of three donors with
the F508del/F508del mutation were used in all studies. CFBE41o- cells, homozygous for the
F508del mutation, and stably expressing F508del-CFTR (hereafter referred to as CFBE cells)
were generously provided by Dr. J.P. Clancy, University of Cincinnati. CFBE cells were studied
between passages 18 and 27, and grown in culture as described in detail [16,17]. Briefly, to
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establish confluent, polarized monolayers, 0.5× 106 CFBE cells were seeded onto 24-mm
Transwell permeable supports or 12mm Snapwell permeable supports (0.4μm pore size, Corn-
ing, Corning, NY) coated with Vitrogen plating medium containing human fibronectin (10 μg/
ml, Collaborative Biomedical Products, Bedford, MA), PureCol (1%, Advanced BioMatrix, San
Diego, CA), and bovine serum albumin (10 μg/ml, Invitrogen) and grown in an air-liquid in-
terface culture at 37°C for 6–9 days, as described [18,19]. To establish confluent, polarized
monolayers of CF-HBE cells, 1 × 106 cells were seeded onto 24-mm Transwell permeable sup-
ports or 250,000 cells were seeded onto 12mm Snapwell permeable supports (0.4-μm pore size,
Corning, Corning, NY) coated with 50μg/ml Collagen type IV (Sigma) and grown in an air-liq-
uid interface culture at 37°C for 3–4 weeks, as described [15]. Cells grown on Transwell filters
were used for biochemical studies and cytokine analysis, and cells grown on Snapwell filters
were used in Ussing chamber experiments.
Bacterial strains and growth conditions
In these studies, we used P. aeruginosa strains PAO1, PA14 and PAK, and six clinical isolates
of P. aeruginosa (three mucoid: SMC1585, SMC5450, SMC5451 and three non mucoid:
SMC1587, SMC1595, SMC1596) isolated from the sputa of six independent CF patients at the
Dartmouth—Hitchcock Medical Center (Hanover, NH, USA). In addition, studies were con-
ducted with Staphylococcus newman and Streptococcus salavari. All P. aeruginosa strains and
Streptococcus salavari were grown and maintained in LB medium (Lysogeny Broth, LB) at
37°C [20]. Staphylococcus newman was grown in THY broth with Oxyrase. For co-culture stud-
ies, P. aeruginosa, Staphylococcus newman or Streptococcus salavari were harvested from over-
night cultures, washed twice in CFBE cell-growth medium, and then suspended in cell-growth
medium without antibiotics or phenol red. The cell suspensions were added in 300 μl of cell
growth medium to the apical face of CFBE or CF-HBE monolayers for 6 hours. For control
monolayers the same volume of fluid, without bacteria, was added to the apical face of CFBE
and CF-HBE cells. None of the P. aeruginosa isolates or Staphylococcus newman and Strepto-
coccus salavari had any effect on LDH release by CFBE cells over the course of the experiment
(n = 3/group), indicating that the bacteria studied had no effect on epithelial cell viability.
Ussing chamber analysis of F508del-CFTR Cl secretion
Ussing chamber measurements of F508del-CFTR Cl secretion were performed as described
[16,17]. Briefly, CFBE and CF-HBE cells grown on Snapwell permeable supports were
mounted in an Ussing chamber (Physiologic Instruments, San Diego, CA) and short circuit
current (Isc) was measured by voltage-clamping the transepithelial voltage across the monolay-
ers to 0 mV with a voltage clamp (Physiologic Instruments). Amiloride (50 μM) was added to
the apical bath solution (5 ml total volume in the apical and basolateral bath solutions) to in-
hibit Isc attributed to sodium reabsorption, and subsequently Isc was stimulated with forskolin
(10 μm), followed by VX-770 (5 μm) to stimulate CFTR mediated Isc, and thiazolidinone
(CFTRinh-172, 20 μm; EMDMillipore, Billerica, MA) to inhibit CFTR-mediated Isc. Data are
expressed as CFTRinh-172 inhibited Isc in μA/cm
2. Data collection and analysis were done with
the Acquire & Analyze Data Acquisition System (Physiologic Instruments). To examine the ef-
fect of P. aeruginosa on F508del-CFTR Cl secretion P. aeruginosa (see above for strains) was
added to the apical side of CFBE and CF-HBE cell monolayers, which have a layer of mucus
overlying cells, at a multiplicity of infection (MOI) of 30:1 for 6 hours in the absence of antibi-
otics, and then Isc was measured as described above. Ussing chamber studies were also con-
ducted to examine the effect of Staphylococcus newman and Streptococcus salavari on VX-809
stimulated F508del-CFTR Cl secretion by CFBE cells, as described above for P. aeruginosa.
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Biochemical determination of apical membrane CFTR and transferrin
receptor
Briefly, the biochemical determination of F508del-CFTR in the apical plasma membrane of
cells was performed by domain selective cell surface biotinylation using EZ-Link Sulfo-
NHS-LC-Biotin (Pierce) at 4°C, as described previously in detail [18,23]. PAO1 was added to
the apical side of CFBE monolayers at a multiplicity of infection (MOI) of 30:1 for 6 hours in
the absence of antibiotics, and, subsequently, biotinylated proteins were isolated by streptavi-
din-agarose beads, eluted into SDS sample buffer, and separated by 7.5% SDS-PAGE. The blots
were probed for F508del-CFTR, Transferrin receptor (TfR) and for Na+-K+-ATPase as a load-
ing control. Western blot analysis of F508del-CFTR, TfR and Na+-K+-ATPase were conducted
by methods described previously [16,21].
Antibodies and reagents
The antibodies used were: mouse monoclonal anti-CFTR antibody (clone 596; University of
North Carolina Cystic Fibrosis Center, Chapel Hill, NC) 1:1000 dilution; mouse monoclonal
anti-TfR (0.5mg/ml, catalog #13–6800, Invitrogen, Camarillo, CA) 1:1000 dilution; mouse
monoclonal anti-Na+-K+-ATPase (DSHB Hybridoma Product a5 developed by D.M. Fam-
brough, Department of Biology, The Johns Hopkins University) was obtained from the Devel-
opmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The
University of Iowa, Department of Biology, Iowa City, IA 52242.; goat anti-mouse IgG ((H
+ L)-HRP Conjugate; BioRad catalog #170–6516) 1:3000 dilution; and goat anti-rabbit IgG ((H
+ L)-HRP Conjugate BioRad catalog #170–6515, Bio-Rad, Hercules, CA) 1:3000 dilution.
Cytokines
IL-6 and IL-8 produced by polarized monolayers of CFBE and CF-HBE cells were measured
using the Bio-Rad Bio-Plex cytokine arrays (Hercules, CA) as described [19,24]. CFBE and
CF-HBE cells were grown on Transwell filters as described above, and P. aeruginosa was added
to the apical side of monolayers at a multiplicity of infection (MOI) of 30:1 for 1 h in the ab-
sence of antibiotics, and subsequently P. aeruginosa was removed by replacing the apical medi-
um with MEM. Five hours after P. aeruginosa was washed from monolayers the apical and
basolateral media were removed for analysis of cytokines.
Data analysis and statistics
Graphpad Prism version 5.0 for Macintosh (Graphpad, San Diego, CA) was used to perform
a statistical analysis of the data. Means were compared using a t-test or ANOVA followed
by Tukeys test, as appropriate. P<0.05 was significant, and all data are expressed as the
mean ± SEM.
Results
VX-809 stimulates F508del-CFTR Cl secretion
VX-809 (3 μM for 48 hours) increased F508del-CFTR Cl secretion by CFBE cells (Fig 1, S1
Table). Three laboratory isolates of P. aeruginosa (PAO1, PA14 and PAK) reduced VX-
809-stimulated F508del-CFTR Cl secretion by 48%, 38% and 43%, respectively, after 6 hours of
co-incubation (See Fig 2, S2 Table for representative traces of F508del-CFTR Cl currents). Ad-
ditional studies were conducted using recent clinical isolates of P. aeruginosa, including three
non-mucoid and three mucoid strains obtained from CF patients at the Dartmouth Hitchcock
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Medical Center [20]. All of the clinical isolates caused a significant reduction in VX-809 stimu-
lated F508del-CFTR Cl secretion in CFBE cells, with a range of 25% to 45% inhibition (Fig 1,
S1 Table). Additional studies were performed to determine if P. aeruginosa also impacted drug
rescued F508del-CFTR Cl secretion in CF-HBE cells in primary culture. As seen in CFBE cells,
Fig 1. A. Effects of VX-809 alone and in combination with P. aeruginosa on CFBE cells. VX-809 (3 μM,
48 hours) increased Cl secretion compared to vehicle treated control in CFBE cells. PA01, PA14, PAK and 6
clinical isolates of P. aeruginosa reduced VX-809-stimulated F508del-CFTR Cl secretion compared to VX-
809 alone. *P<0.05 versus control. **P<0.05 versus VX-809. N = 3 to 46/treatment.
doi:10.1371/journal.pone.0127742.g001
Fig 2. Representative current traces of CFBE cells. Amiloride (50 μM) was added to the apical bath
solution to inhibit the short circuit current (Isc) attributed to sodium reabsorption, and subsequently Isc was
stimulated with forskolin (FK, 10 μm), followed by VX-770 (5 μm), and thiazolidinone (CFTRinh-172, 20 μm;
EMDMillipore, Billerica, MA) to inhibit CFTR-mediated Isc.
doi:10.1371/journal.pone.0127742.g002
Pseudomonas aeruginosa and VX-809 Stimulated Cl Secretion
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PAO1, PA14 and PAK reduced the VX-809-stimulated F508del-CFTR Cl secretion (41%, 60%
and 63%, respectively) (Fig 3, S3 Table). Moreover, three non-mucoid and three mucoid strains
also reduced VX-809 stimulated F508del-CFTR Cl secretion in CF-HBE cells, with a range of
46% to 59% inhibition (Fig 3, S3 Table).
Although P. aeruginosa reduced VX-809 stimulated F508del-CFTR Cl secretion in CFBE cells
and in CF-HBE cells in primary culture, neither Staphylococcus newman nor Streptococcus salavari
had any effect on VX-809 stimulated F508del-CFTR Cl secretion in CFBE cells (Fig 4, S4 Table).
Fig 3. Effects of VX-809 alone and in combination with P. aeruginosa on primary CF-HBE cells. VX-809
(3 μM, 48 hours.) increased Cl secretion compared to vehicle treated control in primary cultures of
CF-HBE cells. PA01, PA14, PAK and 6 clinical isolates of P. aeruginosa reduced VX-809-stimulated
F508del-CFTR Cl secretion compared to VX-809 alone. *P<0.05 versus control. **P<0.05 versus VX-809.
N = 3 donors, from each donor 3 to 19 monolayers of cells were studied/treatment.
doi:10.1371/journal.pone.0127742.g003
Fig 4. PA14 reduced VX-809 (3 μM, 48 hours.) stimulated Cl secretion by CFBE cells.Neither
Staphylococcus newman (Staph) nor Streptococcus salivari (Strep) reduced VX-809-stimulated F508del-
CFTR Cl secretion compared to VX-809 alone. *P<0.01 versus VX-809, Strep and Staph. N = 3/monolayers/
group.
doi:10.1371/journal.pone.0127742.g004
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Recently, as the studies in this report were being written for publication, two groups inde-
pendently reported that co-administration of VX-770 with VX-809 for 48 hours decreased the
ability of VX-809 to increase F508del-CFTR Cl currents in primary cultures of CF-HBE cells
[22,23]. Thus, we conducted additional experiments with the co-administration of VX-809
+ VX-770 (48 hours) to examine the effect of P. aeruginosa on F508del-CFTR Cl secretion. Fig
5, S5 Table demonstrates that VX-809 (3 μM) alone and in combination with VX-770 (5 μM)
for 48 hours stimulated F508del-CFTR Cl secretion, although Cl secretion was less in CF-HBE
cells treated with VX809 + VX-770 compared with cells treated for 48 hrs. with VX-809 alone.
Interestingly, F508del-CFTR Cl secretion was not significantly reduced by VX-770 in CFBE
cells treated with VX-809. However, in both CFBE cells and in CF-HBE cells treated with VX-
809 + VX-770, P. aeruginosa (PAO1 and PA14) reduced F508del-CFTR Cl secretion (Fig 5,
S5 Table).
P. aeruginosa reduces F508del-CFTR in the plasma membrane
Previous studies have shown that VX-809 reduces the degradation of F508del-CFTR in the
proteasome, and increases plasma membrane F508del-CFTR [24]. Thus, studies were con-
ducted to determine if P. aeruginosa reduces VX-809 stimulated F508del-CFTR Cl secretion by
reducing F508del-CFTR in the apical cell membrane of CFBE cells. VX-809 increased the
amount of F508del-CFTR in the apical membrane of CFBE cells as well as in cell lysates (Fig 6,
S1, S2 and S4 Figs). However, P. aeruginosa reversed the VX-809-stimulated increase in
F508del-CFTR in both the plasma membrane and cell lysate (Fig 6, S1, S2 and S4 Figs). By con-
trast, neither VX-809 nor P. aeruginosa had any effect on the amount of transferrin receptor in
the plasma membrane or in cell lysates of CFBE cells (Fig 7, S3 and S4 Figs). Thus, P. aerugi-
nosa reduced VX-809 stimulated F508-CFTR Cl secretion, in part, by decreasing the amount
of F508del-CFTR in the apical plasma membrane.
Fig 5. Effect of P. aeruginosa on F508del-CFTR Cl secretion in CFBE cells (A) and CF-HBE cells (B)
treated with VX-809 alone and VX-809 + VX-770. VX-770 (5 μM) did not significantly alter VX-809 (3 μM)
stimulated Cl secretion in CFBE cells. Both PAO1 and PA14 reduced VX-809 + VX-770 stimulated Cl
secretion in CFBE cells. By contrast VX-770 significantly reduced VX-809 stimulated Cl secretion in CF-HBE
cells. As in CFBE cells both PAO1 and PA14 reduced the VX-809 + VX-770 stimulated Cl secretion. *P<0.05
versus control. **P<0.05 versus VX-809. ***P<0.05 versus VX-809 + VX-770. N = 3 to 6/treatment for
CFBE cells. For CF-HBE cells, N = 3 donors, from each donor 3 to 7 monolayers of cells were studied/
treatment.
doi:10.1371/journal.pone.0127742.g005
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VX-809 has no effect on IL-6 and IL-8 secretion
In a previous study, we reported that neither VX-325 nor Corr4a, investigational compounds
that increase F505del-CFTR Cl secretion, had any effect on cytokine secretion by CFBE cells
treated with vehicle or P. aeruginosa [17]. Thus, studies were conducted to determine if VX-
809 alone or VX-809 + VX-770 reduced cytokine secretion by CFBE and CF-HBE cells. Neither
VX-809 alone nor VX-809 + VX-770 had a significant effect on constitutive IL-6 and IL-8 se-
cretion, or on PAO1 simulated IL-6 and IL-8 secretion in CFBE or CF-HBE cells (Fig 8).
Discussion
This study demonstrates that 3 well characterized laboratory strains and 6 clinical isolates of P.
aeruginosa (3 mucoid and 3 non-mucoid) inhibit the VX-809 and VX-809 + VX-770 stimulat-
ed increase in F508del-CFTR Cl secretion in a cell line (CFBE) and in primary cultures of
CF-HBE cells. The P. aeruginosa induced inhibition of VX-809 stimulated F508del-CFTR Cl
secretion is similar to that reported previously for the effect of P. aeruginosa on wt-CFTR Cl se-
cretion [14,16,27]. The observation that P. aeruginosa reduces VX-809 + VX-770 stimulated
F508del-CFTR Cl secretion, coupled with the fact that ~85% of adult CF patients are colonized
with P. aeruginosa suggests that the modest effect of VX-809 + VX-770 on FEV1 in CF patients
(3–5% increase) may be due in part to chronic infection with P. aeruginosa.
If P. aeruginosa reduces VX-809 + VX-770 stimulated F508del-CFTR Cl secretion in vivo
then two predictions can be made. First, if P. aeruginosa inhibits VX-809 + VX-770 stimulated
Fig 6. Analysis of apical CFTR in the presence of VX-809 alone and in combination with P. aeruginosa.
(A) Western blot of apical membrane F508del-CFTR in CFBE cells treated with vehicle (Control), VX-809
(3 μM) alone, PA14 alone, or VX-809 (3 μM) + PA14. Na+-K+-ATPase is a loading control. *P<0.05 versus all
other groups. N = 4/group. **P<0.05 versus VX-809 alone, ***P<0.05 versus Control. N = 4/group. (B) Top:
Representative western blot of F508del-CFTR in cell lysates of CFBE cells treated with vehicle (Control), VX-
809 (3 μM) alone, PA14 alone, or VX-809 (3 μM) + PA14. Bottom: Representative western blot of Na+-K+-
ATPase (gel loading control) in cell lysates of CFBE cells treated with vehicle (Control), VX-809 (3 μM) alone,
PA14 alone, or VX-809 (3 μM) + PA14 *P<0.05 versus all other groups. **P<0.05 versus VX-809 alone,
***P<0.05 versus Control. N = 4/group. All samples run on the same gel but cut for presentation. N = 4/
treatment.
doi:10.1371/journal.pone.0127742.g006
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F508del-CFTR Cl secretion one would expect to see a disproportional improvement in sweat
[Cl] compared to the improvement in FEV1, since sweat ducts are not infected with P. aerugi-
nosa. Recent clinical trials with VX-809 + VX-770 contain several examples where there is a
disproportional improvement in sweat [Cl] in subjects treated with VX-809 + VX-770 [25].
Fig 7. Analysis of plasmamembrane transferrin receptor in the presence of VX-809 alone and in
combination with P. aeruginosa. (A) Representative western blot of apical plasmamembrane transferrin
receptor (TfR) in CFBE cells treated with vehicle (Control), VX-809 (3 μM), PA14 alone, or VX-809 (3 μM)
+ PA14. ns, not significantly different. N = 3/treatment. (B) Top: Representative western blot of cell lysate TfR
in CFBE cells treated with vehicle (Control), VX-809 (3 μM), PA14 alone, or VX-809 (3 μM) + PA14. Bottom:
Representative western blot of cell lysate Na+-K+-ATPase in CFBE cells treated with vehicle (Control), VX-
809 (3 μM), PA14 alone, or VX-809 (3 μM) + PA14. N = 4/treatment. ns, not significantly different. All samples
run on the same gel but cut for presentation.
doi:10.1371/journal.pone.0127742.g007
Fig 8. Analysis of cytokines production in response to P. aeruginosa in the presence and absence of
CFTRmodulating compounds. VX-809 (3 μM) alone and VX-809 + VX-770 (5 μM) had no effect on
constitutive or PAO1 stimulated IL-6 and IL-8 secretion by CFBE cells (A) or CF-HBE cells (B). All PAO1
treated P<0.05 versus untreated. N = 3-6/treatment.
doi:10.1371/journal.pone.0127742.g008
Pseudomonas aeruginosa and VX-809 Stimulated Cl Secretion
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For example, in Cohort #1 VX-809 + VX-770 (VX-809, 200 mg once per day + VX-770, 250
mg every 12h) decreased sweat [Cl] from day 1 to day 21 by 12.6 mmol/L, a 12.6% decrease but
had no significant effect on FEV1. For Cohort #2, VX-809 + VX-770 (VX-809, 400 mg once
per day + VX-770, 250 mg every 12h) decreased sweat [Cl] from day 1 to day 56 by 9.1 mmol/
L, a 9.1% decrease, and increased FEV1 by 3.6% [25]. Thus, these two examples reveal a discor-
dance between changes in sweat [Cl] and FEV1. Boyle et al. [25] have suggested that the differ-
ential effects of VX-809 + VX-770 on sweat [Cl] and FEV1 may be related to different tissue
distribution of VX-809/VX-770, differences in the biology of CFTR in sweat duct and lungs, or
non-CFTR effects of VX-809/VX-770. We suggest that another reason is that P. aeruginosa,
which infects the lungs but not sweat ducts, inhibits VX-809 + VX-770 stimulated F508del-
CFTR Cl secretion.
In addition, if P. aeruginosa inhibits VX-809 + VX-770 stimulated F508del-CFTR Cl secretion
one would expect to see a disproportional improvement in FEV1 in subjects not infected with P.
aeruginosa compared to those who are infected with P. aeruginosa. However, at the North Ameri-
can CF Conference in 2014 data were presented demonstrating that there was no significant dif-
ference between the effect of VX-809 + VX-770 on FEV1 in subjects positive or negative for P.
aeruginosa [11]. Although this observation is at odds with our conclusion that infection with P.
aeruginosamay reduce the efficacy of VX-809 + VX-770 in vivo, it is important to note that other
bacteria in the CF lungs, including Acinetobacter nosocomialis and Acinetobacter baumannii se-
crete a virulence factor (aCif) that reduces CFTR abundance in CFBE cells [26], thus, it is possible
that infection with other bacterial that are known to reduce CFTR abundance, in addition to P.
aeruginosa, may influence the response to VX-809 + VX-770. Clearly, additional studies are re-
quired to determine if P. aeruginosa, and or infection with other bacteria such as Acinetobacter
that reduces CFTR abundance, suppresses the efficacy of VX-809 + VX-770 in vivo.
In two recent studies, it was reported that VX-770 dramatically reduced the ability of VX-
809 to increase F508del-CFTR Cl secretion [22,23]. This is at odds with clinical trials with VX-
809 + VX-770 that demonstrated significant improvement in FEV1 and several other improve-
ments in clinical outcomes in CF patients homozygous for the F508del-CFTR mutation [11], as
well as the studies in this report in which the combination of VX-809 + VX770 (48 hours) sig-
nificantly increased F508del-CFTR Cl secretion in CFBE cells and in CF-HBE cells (Figs 1–3
and 5, S1–S3 and S5 Tables). Several factors may contribute to the variable effects of VX-809
+ VX-770 on F508del-CFTR Cl secretion by HBE cells, including the possible differential ex-
pression of modifier genes among donors studied that may affect export of F508del-CFTR from
the endoplasmic reticulum, endocytic trafficking of F508del-CFTR and channel open probabili-
ty [27,28]. While additional experiments are required to determine why these studies reach dif-
ferent conclusions regarding the effect of VX-770 on VX-809 stimulated F508del-CFTR Cl
secretion, our data show that P. aeruginosa inhibits both the VX-809 and the VX-809 + VX-770
stimulated increase in F508del-CFTR Cl secretion in primary cultures of CF-HBE cells.
We have shown that several laboratory strains of P. aeruginosa (PAO1, PA14 and PAK) as
well as 6 clinical isolates of P. aeruginosa reduce VX-809 (and VX-809 + VX-770) stimulated
F508del-CFTR Cl secretion. Furthermore, preliminary studies presented by Guimbellot and
colleagues at the 2014 North American Cystic Fibrosis Conference confirm our results that P.
aeruginosa reduces VX-809 stimulated F508del-CFTR Cl secretion [29]. Interestingly, these
authors demonstrated that other bacteria known to colonize the CF lung, including Haemophi-
lus influenza and Staphylococcus aureus, had no effect on F508del-CFTR Cl secretion. Our re-
sults with Staphylococcus newman and Streptococcus salivari demonstrate that these bacteria
also have no effect on VX-809 stimulated F508del-CFTR Cl secretion.
Finally, studies were also conducted to determine if VX-809 alone or VX-809 + VX-770 re-
duced P. aeruginosa induce cytokine production. A reduction of cytokine secretion would be
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beneficial in CF patients since the hyperinflammatory lung milieu that has been linked to
worse clinical outcomes in CF [30]. However, neither VX-809 alone nor VX-809 + VX-770 re-
duced constitutive nor the P. aeruginosa stimulated increase in IL-6 and IL-8 secretion by
CFBE or CF-HBE cells, a result consistent with a previous study in which we demonstrated
that two other “correctors”, VX-325 and Corr 4a, had no effect on the P. aeruginosa induced
inflammatory response by CFBE cells [17]. Taken together these studies from our laboratory
and from others demonstrate that although VX-325, VX-809 and Corr4a increase F508del-
CFTR Cl secretion, these drugs do not modify the hyperinflammatory response of CF airway
cells to P. aeruginosa infection. The most effective drugs for CF patients would ideally enhance
F508del-CFTR Cl secretion and reduce the proinflamatory response to bacterial infection.
Conclusion
Because 85% of adult CF patients are chronically colonized by P. aeruginosa, and because P.
aeruginosa inhibited VX-809 and VX-809 +VX-770 F508del-CFTR Cl secretion by CFBE and
CF-HBE cells, the observation in this paper may explain, in part, why VX-809 + VX-770 has
only modest clinical benefit.
Supporting Information
S1 Fig. Western blots of apical membrane CFTR used to prepare Fig 6A. Vertical line indi-
cates where blot was cut for presentation.
(TIF)
S2 Fig. Western blots of CFTR in cell lysates used to prepare Fig 6B. Vertical line indicates
where blot was cut for presentation purposes. Band near 76 kDa standard was from reprobe
with a non-CFTR antibody.
(TIF)
S3 Fig. Western blots of cell lysate and plasma membrane transferrin receptor expression
used in Fig 7A (plasma membrane) and 7B (cell lysate). Vertical lines indicate where blot
was cut for presentation purposes. Band in top blots near 102 kDa was from a reprobe with a
commercial Na/K/ATPase antibody that did not recognize Na/K/ATPase.
(TIF)
S4 Fig. Na/K/ATPase blots probed with antibody from Developmental Studies Hybridoma
Bank used to normalize CFTR and transferrin to prepare Figs 6 and 7. Vertical lines indicate
where blot was cut for presentation purposes.
(TIF)
S1 Table. Raw data from Fig 1.
(XLSX)
S2 Table. Raw data from Fig 2.
(XLSX)
S3 Table. Raw data from Fig 3.
(XLSX)
S4 Table. Raw data from Fig 4.
(XLSX)
S5 Table. Raw data from Fig 5.
(XLSX)
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